Skin symptoms may clear with biologics in psoriasis, but hidden internal inflammation often persists, contributing to major ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

A new study highlights a significant medical concern for individuals suffering from psoriasis, revealing that even when skin ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

New research shows that in patients with psoriasis, even though their skin responds well to treatment with biologics, ...

Residual inflammation persisted among patients with psoriasis despite optimal disease response to biologic therapies, putting ...

By Dennis Thompson HealthDay ReporterTHURSDAY, May 29, 2025 (HealthDay News) — Belly flab appears to be a stronger warning ...

In a country where chronic skin diseases affect millions, one institution is rewriting the rulebook. Kayakalp Global, based ...

Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...